Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of KB105 for Treatment of TGM-1 Deficient Autosomal Recessive Congenital Ichthyosis

Trial Profile

A Study of KB105 for Treatment of TGM-1 Deficient Autosomal Recessive Congenital Ichthyosis

Planning
Phase of Trial: Phase I/II

Latest Information Update: 22 Oct 2018

At a glance

  • Drugs KB 105 (Primary)
  • Indications Ichthyosis
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Oct 2018 New trial record
    • 17 Oct 2018 According to a Krystal Biotech media release, the company has commenced an underwritten public offering of 60.0 dollar million of its common stock.The company intends to use the net proceeds from this offering, if any, together with its existing cash, cash equivalents and short-term investments to advance the pre-clinical development of KB105 with clinical trial anticipated to commence in the first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top